Cresco Labs (CL) EGM 2024 summary
Event summary combining transcript, slides, and related documents.
EGM 2024 summary
23 Apr, 2026Opening remarks and agenda
Meeting called to order with rules for virtual participation and voting outlined.
Notice of meeting and related materials were mailed to shareholders of record.
Meeting held on July 10, 2024, to address annual general and special matters.
Specific resolutions to be voted on
Board size fixed at eight directors for the ensuing year.
Election of eight directors as nominated in the Management Information Circular, all approved by majority vote.
Appointment of Marcum LLP as auditor and authorization for board to fix remuneration; Marcum LLP reappointed for the next year.
Amended and Restated 2018 Long-Term Incentive Plan approved, increasing share pool by 20,000,000 shares.
Option Exchange Program approved, allowing employees to exchange out-of-the-money options for fewer new options.
Board and executive committee updates
Eight directors elected: Charles Bachtell, Tarik Brooks, Gerald F. Corcoran, Marc Lustig, Thomas J. Manning, Randy D. Podolsky, Michele Roberts, Robert M. Sampson.
Nominees for director positions listed, with no other nominations received.
Latest events from Cresco Labs
- Q1 2026 revenue was $151.3M with $33M adjusted EBITDA and expanded dispensary presence.CL
Q1 20268 May 2026 - All resolutions, including director elections and incentive changes, passed with strong support.CL
EGM 202523 Apr 2026 - Q4 2025 revenue was $162M with margin gains, but net loss was driven by impairment charges.CL
Q4 20255 Mar 2026 - Q2 saw margin and cash flow gains, with growth expected as adult-use markets expand.CL
Q2 20242 Feb 2026 - Q3 2024 saw record cash flow, margin gains, and top market share amid strategic growth moves.CL
Q3 202415 Jan 2026 - Margin and cash flow gains drive growth and expansion despite revenue decline and tax charges.CL
Q4 202425 Dec 2025 - Vertically integrated U.S. cannabis operator launches multi-security shelf offering amid regulatory risks.CL
Registration Filing29 Nov 2025 - Q1 2025 delivered $166M revenue, strong cash flow, and market leadership despite margin pressure.CL
Q1 202525 Nov 2025 - Q2 2025 revenue hit $164M, 25% EBITDA margin, and debt refinancing supports future growth.CL
Q2 202523 Nov 2025